Search

With this, Venus Remedies has secured 525 marketing approvals for its oncology products across 76 Countries [ABSTRACT FROM AUTHOR]

Venus Remedies has informed that it enclosed a press release being issued by the Company titled 'Venus Remedies consolidates in ASEAN, gets marketing approval for six chemotherapy drugs from the Philippine'. The above information is a part of company's filings submitted to BSE. [Extracted from the article]

With this, it has secured 503 marketing approvals for its oncology products across 75 countries [ABSTRACT FROM AUTHOR]

With this, it has secured 503 marketing approvals for its oncology products across 75 countries [ABSTRACT FROM AUTHOR]

The company has secures a marketing authorization from the largest market in the Gulf Cooperation Council region [ABSTRACT FROM AUTHOR]

The company has secures a marketing authorization from the largest market in the Gulf Cooperation Council region [ABSTRACT FROM AUTHOR]

The article offers updates on lung cancer treatment. According to the author, the Peregrine Pharmaceuticals has submitted a clinical protocol with the Drug Controller General of India for a Phase II trial of bavituximab in combination with chemotherapy in patients with non-small cell lung cancer. Meanwhile the National Institute for Health and Clinical Excellence has recommended Alimta for patients who can carry out day-to-day tasks but whose cancer is advanced and unsuited to surgery.

The article provides updates related to the clinical management of leukemia. Genta Inc. has found the potential of its drug Genasense in combination with chemotherapy in patients with chronic lymphocytic leukemia (CLL). The U.S. Food and Drug Administration has accepted Genta's new drug application for Genasense. A clinical trial was initiated by Genitope to assess the use MyVax personalized immunotherapy in treatment of CLL.

Diagnoses of breast cancer, the disfiguring disease most dreaded by American women, rose steadily during the 1980s and now appear to have leveled off. But death rates from the disease have changed little since the 1930s. To some experts, the data indicate that modern medicine is conquering the disease through treatments like chemotherapy and regular screening with mammograms,which can catch the disease at an earlier, more curable stage. But to skeptics, the statistics mean that breast cancer remains an intractable disease and that scientists have yet to find a cure for its most virulent forms. As politically savvy breast cancer activists push for increased federal spending to find a cure, they are asking increasingly skeptical questions about how the money should be spent. [ABSTRACT FROM AUTHOR]

The article focuses on justice Ruth Bader Ginsburg who shares her views on her cancer treatment. Topics discussed include chemotherapy received by her for recurrence of cancer, her views on intention of her retirement, and impact of health and capacity on Republican President Donald Trump in the election year 2020.

Zydus Cadila has received approval from USFDA to initiate clinical trials of Desidustat in Chemotherapy Induced Anemia [ABSTRACT FROM AUTHOR]

The project has been perceived and articulated to get operational by 2021 [ABSTRACT FROM AUTHOR]

INFUGEM is an alcohol-free, clear, colorless, sterile solution of 10mg/mL gemcitabine in 0.9% sodium chloride [ABSTRACT FROM AUTHOR]

The article reports on the agreement between biopharmaceutical company Cell Therapeutics Inc. and North Central Cancer Treatment Group (NCCTG) to conduct a Phase II study of pixantrone in patients with breast cancer. The trial will be conducted through the NCCTG at community clinics and medical centers in Canada and in the U.S. Jack Singer, chief medical officer of Cell Therapeutics, stressed the need for effective and well-tolerated new agents in patients who undergone chemotherapy .

The article reports on the results of a Phase I trial for the BRAF inhibitor, PLX4032, in advanced melanoma. The trial is composed of a dose-escalation study and an evaluation of pharmacokinetics and antitumor responses at the maximum-tolerated dose. It claims that the requirement for BRAF mutations prior to treatment with PLX4032 is another step in personalized cancer therapy.

The article offers world news briefs related to cancer therapy. Roche has announced that the European Commission has approved blockbuster MabThera in combination with chemotherapy for patients with untreated chronic lymphocytic leukemia (CLL). Biotech Cell Genesys has announced positive results from Vital-1, the company's recently terminated Phase III clinical trial. The Phase III trial of pancreatic cancer treatment was halted by Pfizer.

The article reports on the result of the Phase II clinical trial conducted by BioNumerik Pharmaceuticals which assesses the effectiveness of Tevocept drug in the treatment of adenocarcinoma. The study was participated by adenocarcinoma patients were their survival rates have been evaulated with the drug's administration. It reveals that mortality in the Tavocept group declined to 40 percent and survival rate was higher within the group compared to those administered with chemotherapeutic drugs.

The article provides updates on drugs application by several biotechnology companies to the U.S. Food and Drug Administrations (FDA). Advaxis Inc. has filed a new investigational new drug application, which includes phase II protocol for the drug Lovaxin C. Genta Inc. has submitted an amendment to the FDA for its new drug application for Genasense injection plus chemotherapy for patients with refractory chronic lymphocytic leukemia.

The article focuses on the need for more supportive care measures for prevention and treatment of cancer. It has been reported that cancer treatment is shifting towards molecular targeted therapies, which are generally associated with mild side effects, indicating that the need for traditional supportive care measures may decrease in the future. With this, new products with own unique set of side effects needs supportive care measures that will need to change to meet these requirements.

The article offers news briefs related to drug developments for the treatment of lymphoma. An approval is acquired by Millennium Pharmaceuticals Inc. for the use of drug Velcade for the treatment of mantle cell lymphoma. Positive early results on the two studies that evaluates HuMax-CD4 in both cutaneous and non-cutaneous T-cell lymphoma are posted. Drug industries reveal that drug Campath is found superior to the chemotherapy chlorambucil in patients with B-cell chronic lymphocytic leukemia.

The article reports on Roche and Genentech's temporary suspension of patient enrollment in a phase II study evaluating Avastin in colorectal cancer. The phase II trial will evaluate 3,450 stage II and III colorectal cancer patients who will be given adjuvant treatment following surgery. Three regimens will be tried.

The article presents information about cytotoxic drugs used in cancer chemotherapy. Cancer has been the focus of intense and ongoing research and development for a number of years. As of May 2005, there were 399 compounds in development for cancer. By comparison, there are 220 compounds in development for central nervous system therapy, the next most active disease area. However despite the significant interest, this has yet to translate into consistently successful management of the disease, particularly in the more advanced stages.

The article presents information about cytotoxic drugs used in chemotherapy regimens. The differentiation between malignant and normal cells is becoming increasingly apparent and as a result, a plethora of potential drug targets is presented, in the form of altered genes, proteins or corrupted pathways. The increased selectivity conferred by these unique targets offers developers the opportunity to produce more efficacious and less toxic cancer treatments. Most primary tumors can be successfully treated if diagnosed in the early stages.

The article investigates the potential therapeutic benefits of Glivec, a novel antineoplastic agent for hematological malignancies developed by Novartis SA. The novel agent was thought to be the start of a new era in cancer drug design, as it targets the specific molecular abnormality that drives malignant growth in chronic myeloid leukemia. But while showing promising initial results, the success of Glivec therapy is somewhat marred by the emergence of drug-resistant clones.

The article reports on the positive data released by Genentech Inc. on its phase III clinical trials on Herceptin that will help treat patients with breast cancer. The information brings new hope to thousands of women with breast cancer. Herceptin was tested together with chemotherapy drugs most commonly used to treat the disease. However, the news is likely to have a limited impact on the future sales of Perception, in spite of its compelling data.

The article reports global developments related to the biotechnology industry. According to the phase III trial, Genentech Inc.'s anticancer treatment, Avastatin, has shown to improve survival in combination with chemotherapy in Europe. MedImmune Inc. has filed an investigational new drug application with the U.S. Food and Drug Administration for its nasally delivered combination vaccine against child respiratory disease.

The article investigates the potential therapeutic benefits of Glivec in treating patients with chronic myeloid leukemia (CML) by researchers at Novartis AG. Indications showed that a higher dose of the novel antineoplastic agent may improve chances of survival in CML cases. CML patients receiving 800 milligrams of Glivec are more likely to attain complete cytogenetic response compared to the standard dose of 400 milligrams.

Reports that Cell Genesys Inc. has released follow up clinical data from an ongoing phase II trial of Gvax leukemia vaccine which indicate that the therapy is well tolerated and may reduce residual leukemic cells after chemotherapy. Reduction in residual leukemic cells that persist after chemotherapy as indicated by decreased levels of WT-1, a leukemia-associated genetic marker; Form of Gvax vaccine used in both the leukemia and myeloma clinical trials; Decrease in the myeloma-associated circulating protein.

Reports that Roche Inc.'s and Genentech Inc.'s co-developed innovative cancer drug, Avastin, has received a positive recommendation from the European Committee for Medicinal Products for Human Use (CHMP). Recommendation of CHMP that Avastin in combination with other drugs be indicated as first-line treatment of metastatic carcinoma of the colon or rectum; Basis of the recommendation on the data which showed that patients treated with Avastin plus chemotherapy lived 30 percent longer than those receiving chemotherapy alone; Ability of Avastin to increase the amount of time that patients were without disease progression.

Reveals that Rituximab has become the first anticancer agent to achieve sales of over $2 billion in 2003. Marketing of the drug by Genentech and Roche. Clinical trial results for the drug in Europe.

Relates that Marshall Edwards Inc. has commenced a clinical trial evaluating the ability of the anticancer drug, phenoxodiol, as a chemo-sensitizing agent for ovarian cancer treatment. Sites who have already enrolled patients.

Reports that three separate studies carried out by scientists at Ligand Pharmaceuticals Inc. offer support for enhanced activity of chemotherapeutic agents in combination with Targretin in non-small cell lung cancer (NSCLC). Targretin's prevention or reversal of acquired tumor cell resistance to paclitaxel in NSCLC and advanced human breast cancer cell lines; Development of paclitaxel resistance in NSCLC tumor cells.

Reports that Telik Inc. is set to initiate a randomized phase III trial of Telcyta administered as a single agent in non-small cell lung cancer patients who have failed two prior chemotherapy regimens specifically. Number of patients to be enrolled in the clinical trial; Background information on the drug; Researchers' goal to determine whether Telcyta treatment does in fact reduce the risk of mortality.

Reports that Sanofi-Synthelabo has submitted a supplemental New Drug Application (sNDA) in the United States and Europe for Eloxatin in the adjuvant treatment of colorectal cancer. Potential sales from the drug; Relapse incidence for patients with colorectal cancer after surgery.

Reports on the delay of the clinical trials of a cancer drug of Inex Pharmaceuticals. Dependence of original schedule on manufacturing targets of GlaxoSmithKline.

Reports on developments related to antineoplastic agents in the U.S. as of January 14, 2004. Use of Sanofi's Eloxatin drug for colorectal cancer; AstraZeneca's antitumor drug Iressa.

Reports that Aventis Pharmaceuticals Inc.'s Taxotere administered as neo-adjuvant chemotherapy has been shown to increase the five-year survival rates of women with large or locally advanced breast cancer. Comparison of Taxotere with standard neo-adjuvant chemotherapy; Higher rates of breast conserving surgery shown by women receiving Taxotere.

Highlights the fast-track designation received by Cell Therapeutics from the U.S. Food and Drug Administration for the treatment of advanced non-small cell lung cancer. Reasons for granting the status.

Presents Nemod Immunotherapie AG's biodistribution data for its proprietary PankoMab antibody targeting the TA-MUC-1 antigen. Results showing that the drug, when coupled to the radionuclide indium, accumulates strongly and specifically in colon and breast carcinomas.

Reports that Eximias Pharmaceutical Corp. has presented data suggesting that Thymitaq may be effective in disease stabilization in pancreatic cancer. Description of Thymitaq as a novel antifolate that exerts its anticancer activity through direct inhibition of thymidylate synthase.

Discusses results of clinical trials showing that Thalomid and other immunomodulatory drugs demonstrated potential as a treatment targeting the myeloma cell-host interaction and bone marrow microenvironment, according to a study presented by Celgene scientists at the 9th International Myeloma meeting in Spain. Study suggestion that a reduction of the monoclonal protein concentration of at least 50 percent occurred in a third of patients with refractory multiple myeloma after Thalomid monotherapy.

Reports that GlycoGenesis presented positive clinical data demonstrating that the investigational compound GCS-100 killed both a chemotherapy-resistant human lymphoma cell line that over expressed the Bcl-2 protein and an identical non-Bcl-2-over-expressing human lymphoma cell line in vitro. Effectiveness of GCS-100 when administered as a monotherapy; Confirmation that GCS-100 has a spectrum of activity against the chemotherapy-resistant cancers.

Reports on Genta's release of preliminary clinical phase II data supporting the activity of its lead anticancer drug, Genasense, both as single agent and in combination with chemotherapy in patients with mantle cell lymphoma (MCL). Mechanism of action of Genasense; Description of MCL as an aggressive form of non-Hodgkin's lymphoma resistant to chemotherapy and considered incurable with conventional treatment.

Reports the presentation of data at the 39th annual meeting of the American Society of Clinical Oncology showing that elderly patients with advanced non-small cell lung cancer who received Taxotere with a platinum compound experienced an improvement in median survival compared to the combination of vinorelbine and cisplatin. Affirmation that Taxotere/platinum combinations are active first-line treatment options for lung cancer.

Reports that Erbitux, a cancer drug developed by ImClone Systems, has been found to slow the progression of colon cancer stabilizing or reducing tumor growth in more than 50 percent of patients. Release of the data by Merck KGaA of Germany, claiming that data from its European colorectal cancer study demonstrated that Erbitux, in combination with irinotecan, represents an advance in the treatment of patients with metastatic colorectal cancer.

Reports that Abgenix and Amgen presented interim results from a phase II study of ABX-EGF, a human monoclonal antibody, demonstrating that it has antitumor activity when administered as a single-agent treatment to patients with advanced colorectal cancer. Assessment that the fully human nature of ABX-EGF confers potential benefits with virtually no risk of allergic reactions.

Reports on the announcement of Cell Therapeutics of its plan to begin phase I and II studies of its novel camptothecin polymer conjugate in combination with standard chemotherapy in colorectal cancer and as a single agent in small cell lung cancer, in 2004. Recognition of camptothecin as one of fastest growing calsses of anticancer agents.

Reports that Genta has initiated a clinical trial with its lead anticancer drug, Genasense, in patients with advanced breast cancer. Evaluation of the safety and efficacy of Genasense in combination with Aventis' Taxotere and doxorubicin, two standard chemotherapy drugs; Mechanism of action of Genasense.

The article focuses on the report by Merck Serono SA, a division of Merck KGaA, that Erbitux offers an improvement in overall survival when added to first-line Folfiri chemotherapy regimen for metastatic colorectal cancer or mCRC patients with KRAS wild-type tumors in the Crystal study. It says that the study includes an analysis of the predictive value of BRAF status on Erbitux efficacy. It notes that the analysis also shows that patients with KRAS can also benefit from Erbitux treatment.

The article reports on the agreement between Keryx Biopharmaceuticals Inc. and the U.S. Food and Drug Administration for a Phase III colorectal cancer trial. It says that the trial involves special protocol assessment (SPA) for its P13K/Akt pathway inhibitor in patients with refractory metastatic colorectal cancer. It notes that SPA offers a deal that the study design covers the objectives in support of a regulatory submission. It cites that main endpoint of the study is overall survival.